Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8736814 | Clinical Microbiology Newsletter | 2018 | 5 Pages |
Abstract
Meningitis and encephalitis are infections of the central nervous system (CNS) that can range in severity from mild and self-limiting to severe and life threatening. These infections can be caued by a number of bacterial, viral, and fungal pathogens. Appropriate management of these infections is dependent upon an accurate and rapid identification of the infecting organism. Despite diagnostic advances with improved detection and turnaround time, currently, the etiological pathogen in central nervous system infections is identified in only 30 to 50% of symptomatic patients. The development of targeted molecular tests has begun to address these shortcomings, and the recent FDA clearance of the first broadly multiplexed test for meningitis/encephalitis has great potential to improve laboratory diagnosis of these infections. However, a thorough understanding of the performance and limitations of these tests is critical to ensure maximal patient benefit and to mitigate the reporting of potentiality erroneous or misleading results. Part II of this article presents an overview of quality within the diagnostic laboratory and specific approaches to ensure the reliability and the appropriate utilization and interpretation of results generated using targeted and multiplexed molecular diagnostics for meningitis/encephalitis.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Blake W. Ph.D., D(ABMM),